Please Find the Enclosed herewith Audited Results for FY 31 march 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Boston Bio Systems Limited reported audited standalone results for FY25 with revenue from operations of Rs. 19.25 lakhs, up from nil in the previous year. Total expenses rose sharply to Rs. 73.98 lakhs (vs Rs. 14.07 lakhs), driven mostly by other expenses, leading to a net loss of Rs. 54.73 lakhs compared with a loss of Rs. 14.07 lakhs in FY24. The auditor (M/s Nahar V & Company) issued an unmodified opinion, and the board approved the results at its meeting on 30 May 2025. The balance sheet shows total assets of Rs. 1,490.37 lakhs against shareholders' funds of only Rs. 590.45 lakhs, with negative other equity of Rs. 109.77 lakhs. Cash flow from operations was deeply negative at Rs. (458.46) lakhs, which the company funded almost entirely by taking on Rs. 457.48 lakhs in fresh borrowings, pushing non-current borrowings from Rs. 11.62 lakhs to Rs. 459.29 lakhs.
The company is loss-making, burning cash from operations and leaning heavily on debt to stay afloat, which is a red flag for shareholders despite the clean audit opinion. With negative net worth components, rising debt, and no clear earnings visibility, the stock remains a high-risk, speculative name.